15 assets in Fallopian Tube Neoplasm

Therapeutic assets addressing Fallopian Tube Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Fallopian Tube Neoplasm	Eli Lilly and Company	P3	BB (70)
Carboplatin Fallopian Tube Neoplasm	Eli Lilly and Company	P3	BB (70)
Mirvetuximab Soravtansine Fallopian Tube Neoplasm	Eli Lilly and Company	P3	B (60)
Nogitecan Fallopian Tube Neoplasm	Eli Lilly and Company	P3	B (60)
Pembrolizumab Fallopian Tube Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P3	B (60)
Sofetabart Mipitecan Fallopian Tube Neoplasm	Eli Lilly and Company	P3	B (60)
Docetaxel Fallopian Tube Neoplasm	Clinica Universidad de Navarra, Universidad de Navarra	P3	B (57)
Letrozole Fallopian Tube Neoplasm	Swiss GO Trial Group	P3	B (57)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Fallopian Tube Neoplasm	Corcept Therapeutics	P3	B (57)
Oregovamab Fallopian Tube Neoplasm	CanariaBio Inc.	P3	CCC (54)
Catequentinib Fallopian Tube Neoplasm	Wenjun Cheng	P2	CCC (53)
Nivolumab Fallopian Tube Neoplasm	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
ab-1015 Fallopian Tube Neoplasm	Arsenal Biosciences, Inc.	P1	CC (41)
bp1001-a Fallopian Tube Neoplasm	Bio-Path Holdings, Inc.	P1	CC (41)
Felmetatug Vedotin Fallopian Tube Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (41)